Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010-2016)-Reference-Cited by-同舟云学术

Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010-2016)

Published:2018-07 Issue:7 Volume:18 Page:480-485.e3
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Jagannath Sundar,Abonour Rafat,Durie Brian G.M.,Gasparetto Cristina,Hardin James W.,Narang Mohit,Terebelo Howard R.,Toomey Kathleen,Wagner Lynne,Srinivasan Shankar,Kitali Amani,Yue Lihua,Flick E.Dawn,Agarwal Amit,Rifkin Robert M.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference15 articles.

1. Connect MM registry: the importance of establishing baseline disease characteristics;Rifkin;Clin Lymphoma Myeloma Leuk,2015

2. Analysis of common eligibility criteria of randomized controlled trials in newly diagnosed multiple myeloma patients and extrapolating outcomes;Shah;Clin Lymphoma Myeloma Leuk,2017

3. Connect MM®—the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide;Rifkin;Leuk Lymphoma,2016

4. Recognition of early mortality in multiple myeloma by a prediction matrix;Terebelo;Am J Hematol,2017

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison;Leukemia & Lymphoma;2024-02-12

2. Real-World Utilization of Radiation Therapy in Multiple Myeloma: An Analysis of the Connect MM Registry;Practical Radiation Oncology;2023-11

3. Isatuximab plus carfilzomib and dexamethasone in patients with early <i>versus</i> late relapsed multiple myeloma: IKEMA subgroup analysis;Haematologica;2023-08-17

4. The Value of Pharmaceutical Industry-Sponsored Patient Registries in Oncology Clinical Research;The Oncologist;2023-06-07

5. Second- and third-line treatment strategies in multiple myeloma: a referral-center experience;Blood Cancer Journal;2022-12-06